Related Experiment Video
Updated: Jan 17, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Disrupting the epigenetic alliance: structural insights and therapeutic strategies targeting DNMT1-UHRF1
Emadeldin M Kamel1, Mohamed A M Ali2, Ahmed A Allam2
1Chemistry Department, Faculty of Science, Beni-Suef University, Beni-Suef, 62514, Egypt. emad.abdelhameed@science.bsu.edu.eg.
Abstract:
Maintenance DNA methylation relies on a coordinated partnership between DNMT1 and its chromatin cofactor UHRF1. UHRF1's SRA domain flips 5-methylcytosine out of hemimethylated DNA, and UHRF1-installed ubiquitin marks on histone H3 (H3K18/K23Ub; H3Ub₂) and PAF15 (PAF15Ub₂) are recognized by the DNMT1 RFTS domain to relieve autoinhibition and license copying of parental methylation during S phase. Tumors often upregulate this axis to enforce promoter hypermethylation programs, whereas approved azanucleosides act via DNMT1 trapping and are associated with DNA-damage-linked toxicities. Over ~ 15 years of structural work-from the 2008 SRA-DNA complexes to a 2022 cryo-EM structure of DNMT1 engaged with hemimethylated DNA and H3Ub₂-has mapped two tractable sites: the UHRF1-SRA aromatic cage and the ubiquitin-binding surface on DNMT1's RFTS. These insights catalyzed small-molecule discovery. The anthraquinone UM63 validated SRA-pocket engagement but intercalates into DNA; newer non-intercalating SRA-directed inhibitors AMSA-2 (hydroxyanthracene/anthrarobin) and MPB-7 (imidazoquinoline) retain low-micromolar potency. In cells, AMSA-2 and MPB-7 disrupt UHRF1/DNMT1 colocalization at replication foci and induce replication-coupled global hypomethylation, with preferential cytotoxicity in UHRF1-high cancer lines relative to non-transformed cells. Beyond SRA antagonism, DNMT1 can be down-regulated pharmacologically: the non-nucleoside inhibitor GSK-3,484,862 triggers proteasome-dependent DNMT1 degradation alongside hypomethylation, and the first DNMT1-targeting PROTAC (KW0113) achieves selective DNMT1 degradation and growth inhibition in AML models. Remaining hurdles include potency ceilings, nuclear exposure/pharmacokinetics, and adaptive chromatin rewiring upon DNMT1 inhibition; nonetheless, structure-guided optimization and degrader strategies outline a credible path to precision epigenetic therapeutics that directly disrupt the DNMT1-UHRF1 maintenance machinery.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Spreading of Chromatin Modifications
Writers
The writer...
Biosynthesis of Nucleic Acids
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...

